{
    "paper_id": "PMC7201872",
    "metadata": {
        "title": "Photochemical treatment of plasma with amotosalen and long\u2010wavelength ultraviolet light inactivates pathogens while retaining coagulation function",
        "authors": [
            {
                "first": "Yasmin",
                "middle": [],
                "last": "Singh",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Lynette",
                "middle": [
                    "S."
                ],
                "last": "Sawyer",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Linda",
                "middle": [
                    "S."
                ],
                "last": "Pinkoski",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Kent",
                "middle": [
                    "W."
                ],
                "last": "Dupuis",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Jocelyn",
                "middle": [
                    "C."
                ],
                "last": "Hsu",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Lily",
                "middle": [],
                "last": "Lin",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Laurence",
                "middle": [],
                "last": "Corash",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Apheresis plasma (approx. 600 \u00b1 25 mL) was collected from volunteer donors by plasmapheresis on an automated plasmapheresis machine (Haemonetics PCS 2, Haemonetics Corp., Braintree, MA; or Autopheresis\u2010C, Baxter Healthcare Corp., Deerfield, IL) with sodium citrate anticoagulant. For the pathogen inactivation studies, apheresis FFP units were stored frozen (not greater than \u221218\u00b0C) before use. For the plasma function studies, apheresis plasma units were transported at room temperature and processed within 8 hours of collection.",
            "cite_spans": [],
            "section": "Plasma collection ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "The PCT disposable set for treatment of plasma (Baxter Healthcare Corp.) consisted of the following sequentially integrated components: 15 mL of 6 mmol per L amotosalen hydrochloride solution in saline packaged inside a PL 2411 plastic container and protected from UVA light; a 1.3\u2010L PL 2410 plastic container for illumination of plasma; a compound adsorption device (CAD) to reduce the concentration of amotosalen and its photoproducts, which consisted of an adsorbent disk composed of a copolymer of polystyrene and divinylbenzene particles fused with an ultrahigh\u2010molecular\u2010weight polyethylene plastic enclosed in an acrylic housing; and three 400\u2010mL PL 269 plastic containers for storage of the treated plasma.",
            "cite_spans": [],
            "section": "PCT disposable sets and UVA illumination device ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "Plasma was treated by passing through each component in a series of steps. In Step 1, the plasma unit was sterile connected to the amotosalen container and the plasma content passed through the amotosalen container into the illumination container. In Step 2, the plasma containing amotosalen was illuminated with UVA light. In Step 3, the illuminated plasma mixture was passed through the CAD by gravity into the storage containers (Step 4; Fig. 1). The residual amotosalen remaining in plasma after the CAD step is 1.5 \u00b5mol per L or less on average, which is consistently achieved.",
            "cite_spans": [],
            "section": "PCT disposable sets and UVA illumination device ::: MATERIALS AND METHODS",
            "ref_spans": [
                {
                    "start": 441,
                    "end": 447,
                    "mention": "Fig. 1",
                    "ref_id": "FIGREF0"
                }
            ]
        },
        {
            "text": "Illumination of plasma was performed in a UV illumination system (Baxter Model R4R4007, Nova Biomedical, Waltham, MA). The device was capable of illuminating 2 units of plasma per processing cycle. The illuminator delivered a 3 J per cm2 UVA treatment to each plasma unit in approximately 7 to 9 minutes. During illumination plasma units were reciprocally agitated at approximately 70 cycles per minute.",
            "cite_spans": [],
            "section": "PCT disposable sets and UVA illumination device ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "Before addition of amotosalen, plasma units of approximately 585 mL (unless otherwise specified) were inoculated with the applicable pathogen to a final concentration of approximately 106 infectious organisms per mL whenever possible. In all cases, the inoculum volume consisted of not greater than 10 percent of the final plasma volume. Table 1 summarizes the strain and the supplier of each pathogen evaluated in these studies.",
            "cite_spans": [],
            "section": "Inactivation procedures and viability assays for pathogens ::: MATERIALS AND METHODS",
            "ref_spans": [
                {
                    "start": 338,
                    "end": 345,
                    "mention": "Table 1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "Inoculated plasma units were then treated with 150 \u00b5mol per L amotosalen and a 3 J per cm2 UVA treatment. Samples taken after addition of organism, but before addition of amotosalen, were used to determine the pre\u2010PCT input titer. These samples were serially diluted in assay medium or phosphate\u2010buffered saline before viability measurement. The post\u2010PCT samples were taken immediately after UVA illumination. The CAD step was not performed in the pathogen inactivation studies so that measurement of log reduction was a result of illumination of plasma treated with amotosalen only and not affected by potential pathogen affinity for the CAD. The post\u2010PCT samples were assayed for viable organisms undiluted when possible. In some cases, dilution up to 1:10 was required to prevent toxicity of plasma in the culture system. Table 1 also summarizes the biological assays used for quantifying the number of viable organisms. Detailed assay procedures are as described in the respective references. Pre\u2010 and post\u2010PCT titers were quantified with standard assays. The Reed\u2010Muench method was used where end\u2010dilutions were required for quantification.\n22\n Four replicate experiments (unless otherwise specified) for each organism were performed with four independent units (or pools) of plasma.",
            "cite_spans": [],
            "section": "Inactivation procedures and viability assays for pathogens ::: MATERIALS AND METHODS",
            "ref_spans": [
                {
                    "start": 825,
                    "end": 832,
                    "mention": "Table 1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "The level of inactivation was calculated as log\u2010reduction with the formula",
            "cite_spans": [],
            "section": "Inactivation procedures and viability assays for pathogens ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "\n\nLog\u2010reduction = Log(pre\u2010PCT titer/post\u2010PCT titer).\n\n",
            "cite_spans": [],
            "section": "Inactivation procedures and viability assays for pathogens ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "The pre\u2010PCT and post\u2010PCT titers were expressed in scientific notations. The mean level of inactivation and standard deviation (SD) were determined.",
            "cite_spans": [],
            "section": "Inactivation procedures and viability assays for pathogens ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "The total target volume in the illumination container was 600 \u00b1 25 mL, composed of 585 \u00b1 25 mL of plasma and 15 mL of amotosalen solution. The nominal amotosalen concentration was approximately 150 \u00b5mol per L. Each unit of plasma containing amotosalen was illuminated with a 3 J per cm2 UVA treatment on the R4R4007 illumination device. Plasma samples for evaluation of coagulation factor activity were taken before the addition of amotosalen (baseline, pre\u2010PCT) and after PCT including CAD treatment (post\u2010PCT). Samples were snap\u2010frozen and stored at or below \u221265\u00b0C before testing.",
            "cite_spans": [],
            "section": "PCT of fresh plasma for plasma function studies ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "Soluble fibrinogen (Factor [F]I) was measured with a modified Clauss assay in which the clotting time of a diluted plasma sample, after conversion by thrombin into insoluble fibrin, is compared to a standard curve prepared with reference plasma of known fibrinogen concentration. Coagulation factors were assayed with one\u2010stage prothrombin time (PT)\u2010based clotting assays (FII, FV, FVII, FX) or one\u2010stage activated partial thromboplastin time (APTT)\u2010based clotting assays (FVIII, F IX, FXI). The clotting time of a mixture of diluted test plasma sample and plasma deficient in the factor being quantified was compared with a reference curve constructed from the clotting times of five dilutions, ranging from 1:5 to 1:320, of plasma with known activity mixed with deficient plasma. These coagulation tests, as well as the PT and APTT, were performed on an automated coagulation analyzer (MLA Electra 1400C or 1600C, Instrumentation Laboratory Co., Lexington, MA). Reagents included brain thromboplastin (Hemoliance, Instrumentation Laboratory Co.), Platelin L (bioM\u00e9rieux, Durham, NC), and congenital factor\u2013deficient substrate. The endpoint of all tests was the formation of a clot detected photooptically and measured in seconds. The level of the factor being measured was inversely proportional to the time it takes for a clot to form. Factor assay control plasma (FACT; George King Biomedical, Inc., Overland Park, KS) was used as the reference standard for the coagulation factor assays.",
            "cite_spans": [],
            "section": "Measurement of in vitro coagulation function ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "FXIII was measured with the research\u2010use\u2010only FXIII kit (Berichrom, Dade Behring, Marburg, Germany). FXIII, activated by thrombin, releases an activation product that leads to a series of reactions resulting in a decrease in nicotinamide adenine dinucleotide (NADH), detected by monitoring absorbance at 340 nm. The assay was performed on a clot timer (BCT, Dade Behring), and standard human plasma (Dade Behring) was used as the reference standard.",
            "cite_spans": [],
            "section": "Measurement of in vitro coagulation function ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "The von Willebrand factor:ristocetin cofactor (VWF:RCo) activity was measured with the BC von Willebrand reagent (Dade Behring). In the assay, lyophilized PLTs are agglutinated by the VWF in the presence of ristocetin, resulting in a decrease in turbidity measured by the change in absorbance on the Behring clot timer. FACT was used as the reference standard.",
            "cite_spans": [],
            "section": "Measurement of in vitro coagulation function ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "Protein C (PC) and protein S (PS) were measured with kits (Staclot PC kit and the Staclot PS kit, respectively, both from Diagnostica Stago, Asnieres, France). PC and PS assays were based on the prolongation of the APTT resulting from inactivation of FV and FVIII by activated PC. The activator in the PC assay is an extract of Agkistrodon c. contortrix snake venom; the activator in the PS assay is activated PC. The tests were performed on the Behring clot timer. A unicalibrator (Diagnostica Stago) a multi\u2010parametric calibrator, was used as the reference standard.",
            "cite_spans": [],
            "section": "Measurement of in vitro coagulation function ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "Antithrombin was measured with a kit (Stachrom ATIII, Diagnostica Stago). Plasma containing antithrombin was incubated with a known excess of thrombin. A chromogenic substrate, imidolyzed by the remaining thrombin, was detected photooptically on the MLA Electra 1400C or 1600C coagulation analyzer. FACT was used as the reference standard.",
            "cite_spans": [],
            "section": "Measurement of in vitro coagulation function ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "\u03b12\u2010Antiplasmin was quantified with reagents from Diagnostica Stago. In this chromogenic method, plasmin was added in excess to the test plasma, resulting in the formation of antiplasmin\u2010plasmin complexes. The concentration of residual plasmin is measured by its amidolytic activity on a chromogenic substrate measured at 405 nm. \u03b12\u2010Antiplasmin concentration is inversely proportional to the residual plasmin concentration and is determined by color intensity. This analysis was performed by Esoterix Laboratories (Aurora, CO) with an analyzer (STA, Diagnostica Stago).",
            "cite_spans": [],
            "section": "Measurement of in vitro coagulation function ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "The mean and SD were determined for each coagulation parameter quantified. The activity of each coagulation parameter remaining after PCT was expressed as percent retention of the pretreatment (baseline) activity. Comparison of the PT and APTT was based on the prolongation of the clotting time after PCT relative to baseline.",
            "cite_spans": [],
            "section": "Measurement of in vitro coagulation function ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "PCT with 150 \u00b5mol per L amotosalen and a 3 J per cm2 UVA treatment inactivated a wide variety of viruses, including enveloped, nonenveloped, DNA, and RNA viruses in plasma (Table 2). Initial viral titers (pre\u2010PCT) of 104 to 106 infectious viruses per mL were achieved for all viruses except for hepatitis B virus (HBV) and hepatitis C virus (HCV). The highest available titers were used in all cases, whenever possible, to achieve the maximum dynamic range of infectivity.",
            "cite_spans": [],
            "section": "PCT inactivation of viruses in plasma ::: RESULTS",
            "ref_spans": [
                {
                    "start": 173,
                    "end": 180,
                    "mention": "Table 2",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "PCT inactivated a mean of greater than 6.8 logs and greater than 6.4 logs of cell\u2010free and cell\u2010associated human immunodeficiency virus\u2010type 1 (HIV\u20101), respectively. No biologically active HIV\u20101 were detected in any of the test samples for four replicate experiments (Table 2). Similarly, human T\u2010cell lymphotropic virus\u2010I (HTLV\u2010I) and HTLV\u2010II were sensitive to PCT and mean log\u2010reductions of at least 4.5 and greater than 5.7, respectively, were obtained.",
            "cite_spans": [],
            "section": "PCT inactivation of viruses in plasma ::: RESULTS",
            "ref_spans": [
                {
                    "start": 268,
                    "end": 275,
                    "mention": "Table 2",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "Inactivation of HBV and HCV by PCT was measured in nonimmune chimpanzees transfused with the entire unit of amotosalen\u2010 and UVA\u2010treated plasma that was previously inoculated with 104.5 CID50 of HBV or HCV (Table 2). Inactivation of each virus was assayed in two chimpanzees. None of the animals in either the HBV or the HCV study showed evidence of viral hepatitis during a 6\u2010month follow\u2010up with serologic, viral nucleic acid, biochemical, or histologic examination of liver biopsies, demonstrating an inactivation of greater than 4.5 logs for both viruses. Further evidence of PCT inactivation of hepadna virus and flaviviridae was demonstrated with, respectively, the model systems duck hepatitis B virus (DHBV) and bovine viral diarrhea virus (BVDV; Table 2). PCT inactivated 4.4 to 4.5 logs of DHBV and at least 6.0 logs of BVDV.",
            "cite_spans": [],
            "section": "PCT inactivation of viruses in plasma ::: RESULTS",
            "ref_spans": [
                {
                    "start": 206,
                    "end": 213,
                    "mention": "Table 2",
                    "ref_id": "TABREF1"
                },
                {
                    "start": 754,
                    "end": 761,
                    "mention": "Table 2",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "In plasma, PCT inactivated high levels of recently emerging viruses. Mean log\u2010reductions of at least 6.8 and at least 5.5 were achieved for West Nile virus (WNV) and severe acute respiratory syndrome coronavirus (SARS\u2010CoV), respectively (Table 2). PCT inactivated a mean of 5.1 logs of nonenveloped Bluetongue virus and at least 6.8 logs of nonenveloped human adenovirus 5 (Table 2).",
            "cite_spans": [],
            "section": "PCT inactivation of viruses in plasma ::: RESULTS",
            "ref_spans": [
                {
                    "start": 238,
                    "end": 245,
                    "mention": "Table 2",
                    "ref_id": "TABREF1"
                },
                {
                    "start": 374,
                    "end": 381,
                    "mention": "Table 2",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "Gram\u2010positive Staphylococcus epidermidis and gram\u2010negative Klebsiella pneumoniae and Yersinia enterocoliticus were sensitive to PCT. High levels of inactivation were achieved in plasma (Table 3). Initial pre\u2010PCT bacterial levels of 106.6 to 106.7 colony\u2010forming units (CFU) per mL were achieved with all bacterial species. PCT with 150 \u00b5mol per L amotosalen and a 3 J per cm2 UVA treatment resulted in complete inactivation with no viable bacteria remaining in any of the test plasma samples in all four replicates. Mean log\u2010reductions achieved were greater than 7.3 for S. epidermidis and Y. enterocoliticus and greater than 7.4 for K. pneumoniae.",
            "cite_spans": [],
            "section": "PCT inactivation of bacteria in plasma ::: RESULTS",
            "ref_spans": [
                {
                    "start": 186,
                    "end": 193,
                    "mention": "Table 3",
                    "ref_id": "TABREF2"
                }
            ]
        },
        {
            "text": "Spirochetes Treponema pallidum, which causes syphilis, and Borrelia burgdorferi, which causes Lyme disease, were also sensitive to PCT. No viable organisms were detected after PCT in the test plasma samples in all four replicates, demonstrating mean log reductions of >5.9 and >10.6, respectively.",
            "cite_spans": [],
            "section": "PCT inactivation of bacteria in plasma ::: RESULTS",
            "ref_spans": []
        },
        {
            "text": "PCT inactivation studies of Plasmodium falciparum, the protozoan that causes malaria, Trypanosoma cruzi, the pathogen that causes Chagas\u2019 disease, and Babesia microti, an emerging protozoan causing babesiosis, exhibited mean log reductions of at least 6.9 for P. falciparum, greater than 5.0 for T. cruzi, and greater than 5.3 for B. microti (Table 4). In four replicate experiments, 150 \u00b5mol per L amotosalen and a 3 J per cm2 UVA treatment resulted in no detectable T. cruzi and B. microti in the test plasma samples.",
            "cite_spans": [],
            "section": "PCT inactivation of protozoa in plasma ::: RESULTS",
            "ref_spans": [
                {
                    "start": 343,
                    "end": 350,
                    "mention": "Table 4",
                    "ref_id": "TABREF3"
                }
            ]
        },
        {
            "text": "Evaluation of a comprehensive panel of coagulation parameters showed that PCT conserved coagulation function within levels suitable for transfusion support.\n23\n On average, the PT and APPT were prolonged after PCT by 1.0 and 4.3 seconds, respectively (Table 5). Fibrinogen, FVII, and FVIII were retained, on average, 72 to 78 percent of the initial pre\u2010PCT activity. All other coagulation parameters retained at least 82 percent of baseline activity, with FV, FXIII, and VWF:RCo retaining at least 92 percent. Antithrombotic proteins (PC, PS, antithrombin) demonstrated a high level of activity retention (Table 6), ranging between 95 and 98 percent of the initial pre\u2010PCT level. \u03b12\u2010Antiplasmin was retained at 80 percent of baseline activity. Coagulation factor and antithrombotic protein activities fell within the reported reference ranges for conventional plasma.\n24\n\n",
            "cite_spans": [],
            "section": "In vitro coagulation function of plasma after PCT ::: RESULTS",
            "ref_spans": [
                {
                    "start": 252,
                    "end": 259,
                    "mention": "Table 5",
                    "ref_id": "TABREF4"
                },
                {
                    "start": 606,
                    "end": 613,
                    "mention": "Table 6",
                    "ref_id": "TABREF5"
                }
            ]
        },
        {
            "text": "These studies showed that PCT with amotosalen and UVA light is effective against a broad range of pathogens in plasma. This finding is not surprising based on the pathogen inactivation efficacy previously demonstrated for PLTs with the same dose of amotosalen and same dose of UVA light.\n15\n, \n16\n, \n17\n, \n18\n, \n19\n, \n20\n The levels of inactivation for representative viruses, bacteria, and protozoa were measured with PCT conditions developed for the commercial application of FFP.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "PCT inactivated high levels of enveloped viruses including HIV\u20101, HBV, and HCV in plasma. Effectiveness against HBV was initially shown by inactivation of DHBV, an established infectivity model for human HBV.\n25\n A chimpanzee infectivity model was then used to confirm the level of inactivation of HBV in plasma. Effectiveness against HCV was initially shown by inactivation of BVDV, a flavivirus and model for human HCV.\n26\n Inactivation of HCV was then confirmed with the chimpanzee infectivity model as well. PCT is also effective against other flaviviruses such as WNV and, in preliminary studies, dengue virus (data not shown), examples of new pathogens that are of increasing concern to blood centers in North America.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "PCT with amotosalen is very effective against cell\u2010associated HIV\u20101 and against cell\u2010associated HTLV\u2010I and HTLV\u2010II viruses in plasma, demonstrating that amotosalen molecules readily permeate the cell membrane. The ability of the photochemical reagent to permeate the cell membrane as well as nuclear membrane is crucial because some blood\u2010borne viruses exist partially or largely associated with cells. Methylene blue treatment of plasma, for example, is not effective against cell\u2010associated or intracellular viruses.\n11\n The efficacy of the methylene blue system against intracellular viruses depends on the efficacy of filtration or freeze\u2010thaw to quantitatively disrupt WBCs.\n8\n, \n27\n Recent studies, however, demonstrate that conventional WBC filters fail to eliminate cell\u2010associated cytomegalovirus and HTLV\u2010I from PLT products.\n28\n, \n29\n Thus the methylene blue system is ineffective against these viruses.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "The cumulative viral inactivation data in PLTs and plasma would predict that PCT is effective against the majority of enveloped viruses, DNA, or RNA, extracellular or intracellular. Thus PCT has the potential to inactivate new and emerging enveloped viruses and prevent them from entering the blood supply. Indeed, it was found that SARS\u2010CoV was inactivated by PCT in both PLTs and plasma.\n15\n\n",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Nonenveloped viruses are less common as labile blood component transfusion\u2010transmitted pathogens. Human parvovirus B19, and in very rare cases hepatitis A virus (HAV), however, have been transmitted by component blood transfusion.\n30\n, \n31\n A ubiquitous nonenveloped virus, TT virus, has been reported to be transmitted through the blood supply in Japan, but has yet to be directly linked with a specific disease state.\n32\n\n",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "The efficacy of PCT against nonenveloped viruses in plasma continues to be evaluated and is expected to be similar to the results obtained for PLTs.\n16\n In these studies, inactivation experiments were only performed with two nonenveloped viruses, bluetongue virus and human adenovirus 5, as examples. Inactivation results comparable to the PLT experiments were obtained. Owing to the low permeability of the capsid, some nonenveloped viruses show little or no inactivation by PCT. The picornaviruses are known to be the most difficult to inactivate by chemical or physical means.\n33\n The tight capsid structure of picornaviruses such as HAV, polio virus, and encephalomyocarditis virus are thought to exclude even low\u2010molecular\u2010weight compounds such as psoralens from the interior of the virus and PCT is ineffective against these viruses. Human parvovirus B19 and human adenovirus 5, however, were found sensitive to PCT in PLTs.\n16\n, \n34\n The level of inactivation for these nonenveloped viruses can be increased by incubating the spiked blood products with amotosalen before illumination with UVA light.\n34\n\n",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "The methylene blue system also showed variable efficacy against nonenveloped viruses, ranging from ineffective to complete inactivation.\n8\n Another system for treatment of plasma, the S/D system, is ineffective against nonenveloped viruses. S/D inactivates viruses by disrupting the viral membrane.\n10\n\n",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "PCT is effective for inactivation of gram\u2010positive S. epidermidis and gram\u2010negative K. pneumoniae and Yersinia enterocolitica. Y. enterocolitica are cryophilic bacteria that can grow in cold temperatures. High levels of inactivation were achieved for all of these bacteria in plasma. Although transfusion\u2010transmitted bacteremia is not considered a serious problem for transfusion of FFP, it is reassuring to have a pathogen inactivation process that inactivates bacteria as well as viruses. In these studies, inactivation of two spirochetes, T. pallidum and B. burgdorferi, in plasma was also demonstrated. T. pallidum, which causes syphilis, is the only bacteria routinely screened for in blood banks. Under experimental conditions, B. burgdorferi has been reported to remain viable in frozen plasma for more than 1 month.\n35\n PCT has been shown to be effective against these agents and high levels of inactivation were obtained in plasma.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "On an international level, other organisms such as T. cruzi (Chagas\u2019 disease), P. falciparum (malaria), and B. microti (babesiosis) may be more of a concern than bacteria for frozen plasma because, like viruses, they do not require growth during storage to be a transfusion risk. P. falciparum and B. microti are intracellular pathogens, as discussed above, and are resistant to methylene blue treatment.\n11\n\n",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Experiments with plasma are ongoing to measure the level of WBC inactivation by PCT. Based on previous studies with PLTs, it is anticipated that high levels of WBC inactivation could be demonstrated in plasma.\n21\n Overall, the results presented here show that PCT offers the benefit of a broad spectrum of pathogen inactivation. Neither the methylene blue system nor the S/D system for plasma has shown this broad pathogen inactivation profile.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "These studies also confirmed maintenance of adequate plasma coagulation and antithrombotic protein function after PCT. Because FFP is transfused primarily as a replacement for the liver\u2010derived coagulation factors FII, FV, FVII, F IX, FX, and FXI, in vitro studies to evaluate plasma function after processing with PCT were conducted for a panel of coagulation factors, antithrombotic proteins, and clotting time. The proteins most affected by PCT were fibrinogen and FVIII. The changes in coagulation proteins observed in plasma treated with PCT were also associated with slight prolongation in PT and APTT. The slight changes in PT and APTT after PCT, however, were not associated with any adverse clinical observations.\n36\n, \n37\n, \n38\n, \n39\n\n",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Levels of the anticoagulant PC and PS and antithrombin were relatively unaffected by PCT and \u03b12\u2010antiplasmin was conserved by 80 percent. Previous studies on cryoprecipitate prepared from PCT plasma yielded approximately 95 and 88 percent activity retention for fibrinogen and FVIII, respectively, compared to cryoprecipitate prepared from untreated plasma.\n40\n Furthermore, cryosupernatant prepared from PCT plasma retained adequate levels of critical plasma proteins for plasma exchange therapy in acute thrombocytopenic purpura. The data indicate good preservation of hemostasis control proteins such as PS, \u03b12\u2010antiplasmin, and VWF\u2010cleaving protease activity.\n41\n\n",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "From a blood center perspective, the adoption of PCT would enhance safety of blood products and potentially decrease the number of donors rejected. PCT is easily integrated into the plasma preparation system by its ability to treat individual units of fresh apheresis plasma and small pools (three) of whole blood\u2013derived plasma. For further ease of use, PCT is compatible with the existing plasma collection procedures, FFP processing, and distribution methods in use in blood centers. This PCT system allows rapid illumination and processing of plasma units and utilizes the same illumination device developed for pathogen inactivation of PLT concentrates. Thus, both plasma and PLTs can be treated with a similar processing system and the same illumination device.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "In summary, photochemically treated plasma is functionally similar to untreated conventional plasma with the added benefit of pathogen inactivation.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "The authors thank the following investigators for conducting the pathogen inactivation studies: Bernard Guillemain, MD, HTLV; Krishna Murthy, VD, and Harvey Alter, MD, HBV and HCV; Patricia Marion, PhD, DHBV; Kristen Bernard, PhD, WNV; Sheila Lukehart, PhD, T. pallidum; Robert Lane, MD, B. burgdorferi; Phillippe Grellier, MD, P. falciparum; and Wesley Van Voorhis, PhD, T. cruzi; Jorge Benach, PhD, B. microti. We also appreciate the following individuals for their contributions in the development of the INTERCEPT plasma product: Jocelyn Smyers, Betsy Donnelly, Lainie Corten, Meisa Propst, Reydan Mababangloob, Adam Sampson\u2010Johannes, John Kinsey, Debbie Hanson, Treva Peterson, Melchor Dolor, Margaret Rheinschmidt, MT, and George Cimino, PhD.",
            "cite_spans": [],
            "section": "ACKNOWLEDGMENTS",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: \nThe origin of the test pathogens and established biological methods used to detect and quantify viability\n\n",
            "type": "table"
        },
        "TABREF1": {
            "text": "Table 2: \nPCT inactivates enveloped and nonenveloped viruses in plasma at high initial titers\n*\n\n",
            "type": "table"
        },
        "TABREF2": {
            "text": "Table 3: \nPCT inactivates gram\u2010positive and gram\u2010negative bacteria and spirochetes in plasma at high initial titers\n*\n\n",
            "type": "table"
        },
        "TABREF3": {
            "text": "Table 4: \nPCT inactivates protozoa in plasma at high initial titers\n*\n\n",
            "type": "table"
        },
        "TABREF4": {
            "text": "Table 5: \nMaintenance of clotting time and plasma coagulation factor activity after PCT\n*\n\n",
            "type": "table"
        },
        "TABREF5": {
            "text": "Table 6: \nMaintenance of plasma antithrombotic protein activity after PCT\n*\n\n",
            "type": "table"
        },
        "FIGREF0": {
            "text": "Figure 1: \nThe PCT system for plasma. The PCT system consists of a UVA illumination device and an integral disposable set. The device can illuminate 2 units of plasma per processing cycle. The disposable set provides a single\u2010use, closed, integrated system for pathogen inactivation treatment of a plasma unit. The integrated disposable set is composed of the following sterile components: an amotosalen (S\u201059) container, a plastic illumination container, a CAD, and three plastic storage containers. The processing steps are as described under Materials and Methods section. SCD = sterile connection device.\n",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Blood collection and transfusion in the United States in 1997",
            "authors": [],
            "year": 2002,
            "venue": "Transfusion",
            "volume": "42",
            "issn": "",
            "pages": "1253-60",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Inactivation of viruses found with plasma proteins",
            "authors": [],
            "year": 1991,
            "venue": "Biotechnology",
            "volume": "19",
            "issn": "",
            "pages": "417-30",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization",
            "authors": [],
            "year": 1994,
            "venue": "Transfusion",
            "volume": "34",
            "issn": "",
            "pages": "521-6",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "",
            "authors": [],
            "year": 2002,
            "venue": "Important new drug warning [monograph on the Internet].",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "Routine use of platelet components prepared with photochemical treatment (INTERCEPT platelets): impact on clinical outcomes and costs",
            "authors": [],
            "year": 2004,
            "venue": "Blood",
            "volume": "104",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Fundamentals of the psoralen\u2010based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma",
            "authors": [],
            "year": 2001,
            "venue": "Semin Hematol",
            "volume": "38",
            "issn": "Suppl",
            "pages": "4-11",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates",
            "authors": [],
            "year": 2005,
            "venue": "Transfus Med",
            "volume": "15",
            "issn": "",
            "pages": "269-76",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long\u2010wavelength ultraviolet light",
            "authors": [],
            "year": 2005,
            "venue": "Transfusion",
            "volume": "45",
            "issn": "",
            "pages": "580-90",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "In vitro photochemical inactivation of cell\u2010associated human T\u2010cell leukemia virus Type I and II in human platelet concentrates and plasma by use of amotosalen",
            "authors": [],
            "year": 2005,
            "venue": "Transfusion",
            "volume": "45",
            "issn": "",
            "pages": "1151-9",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "Photochemical treatment of platelet concentrates with amotosalen and long\u2010wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria",
            "authors": [],
            "year": 2004,
            "venue": "Transfusion",
            "volume": "44",
            "issn": "",
            "pages": "1496-504",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long\u2010wavelength UV",
            "authors": [],
            "year": 2003,
            "venue": "Antimicrob Agents Chemother",
            "volume": "47",
            "issn": "",
            "pages": "475-9",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "Practice Guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy",
            "authors": [],
            "year": 1996,
            "venue": "Anesthesiology",
            "volume": "84",
            "issn": "",
            "pages": "732-47",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long\u2010wavelength ultraviolet irradiation",
            "authors": [],
            "year": 2005,
            "venue": "Transfusion",
            "volume": "45",
            "issn": "",
            "pages": "1459-63",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA",
            "authors": [],
            "year": 1998,
            "venue": "Blood",
            "volume": "91",
            "issn": "",
            "pages": "2180-8",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "A simple method of estimating fifty\u2010per cent endpoints",
            "authors": [],
            "year": 1938,
            "venue": "Am J Hyg",
            "volume": "27",
            "issn": "",
            "pages": "493-7",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "Quality of therapeutic plasma\u2010requirements for marketing authorization",
            "authors": [],
            "year": 2002,
            "venue": "Thromb Res",
            "volume": "107",
            "issn": "Suppl. 1",
            "pages": "S47-51",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "In vitro characterization of solvent/detergent\u2010treated human plasma and of quarantine fresh frozen plasma",
            "authors": [],
            "year": 1998,
            "venue": "Vox Sang",
            "volume": "74",
            "issn": "Suppl 1",
            "pages": "219-23",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "The molecular biology of the hepatitis B viruses",
            "authors": [],
            "year": 1987,
            "venue": "Annu Rev Biochem",
            "volume": "56",
            "issn": "",
            "pages": "651-93",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "Isolation of a cDNA clone derived from a blood\u2010borne non\u2010A, non\u2010B viral hepatitis genome",
            "authors": [],
            "year": 1989,
            "venue": "Science",
            "volume": "244",
            "issn": "",
            "pages": "359-62",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "Elimination of both cell\u2010free and cell\u2010associated HIV infectivity in plasma by a filtration/methylene blue photoinactivation system",
            "authors": [],
            "year": 2000,
            "venue": "Transfusion",
            "volume": "40",
            "issn": "",
            "pages": "1081-7",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "Assessment of removal of human cytomegalovirus from blood components by leukocyte depletion filters using real\u2010time quantitative PCR",
            "authors": [],
            "year": 2004,
            "venue": "Blood",
            "volume": "103",
            "issn": "",
            "pages": "1137-9",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF21": {
            "title": "Persistence of HTLV\u2010I in blood components after leukocyte depletion",
            "authors": [],
            "year": 2002,
            "venue": "Blood",
            "volume": "100",
            "issn": "",
            "pages": "677-81",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF22": {
            "title": "Current prevalence and incidence of infectious disease markers and estimated window\u2010period risk in the American Red Cross blood donor population",
            "authors": [],
            "year": 2002,
            "venue": "Transfusion",
            "volume": "42",
            "issn": "",
            "pages": "975-9",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF23": {
            "title": "Presence and significance of parvovirus B19 in blood and blood products",
            "authors": [],
            "year": 1998,
            "venue": "Biologicals",
            "volume": "26",
            "issn": "",
            "pages": "89-94",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF24": {
            "title": "Transfusion\u2010transmissible infections",
            "authors": [],
            "year": 1998,
            "venue": "Curr Opin Hematol",
            "volume": "5",
            "issn": "",
            "pages": "396-405",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF25": {
            "title": "Infection with TT virus, a novel transfusion\u2010transmissible DNA virus, in haemophiliacs and in blood products",
            "authors": [],
            "year": 1999,
            "venue": "Br J Haematol",
            "volume": "105",
            "issn": "",
            "pages": "1114-9",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF26": {
            "title": "Photochemical inactivation of viruses with psoralens: an overview",
            "authors": [],
            "year": 1992,
            "venue": "Blood Cells",
            "volume": "18",
            "issn": "",
            "pages": "7-25",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF27": {
            "title": "Inactivation of parvovirus B19 in platelets by Helinx technology",
            "authors": [],
            "year": 2004,
            "venue": "Transfusion",
            "volume": "44",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF28": {
            "title": "Transmission of tick\u2010borne agents of disease by blood transfusion: a review of known and potential risks in the United States",
            "authors": [],
            "year": 2000,
            "venue": "Transfusion",
            "volume": "40",
            "issn": "",
            "pages": "274-84",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF29": {
            "title": "Fresh frozen plasma prepared with amotosalen HCl (S\u201059) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies",
            "authors": [],
            "year": 2005,
            "venue": "Transfusion",
            "volume": "45",
            "issn": "",
            "pages": "1362-72",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF30": {
            "title": "Pharmacokinetic study of FFP photochemically treated with amotosalen (S\u201059) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin",
            "authors": [],
            "year": 2002,
            "venue": "Transfusion",
            "volume": "42",
            "issn": "",
            "pages": "1302-7",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF31": {
            "title": "Therapeutic plasma exchange (TPE) for thrombotic thrombocytopenic purpura (TTP) using plasma prepared with photochemical treatment (INTERCEPT plasma)",
            "authors": [],
            "year": 2004,
            "venue": "Blood",
            "volume": "104",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF32": {
            "title": "Pathogen inactivated fresh frozen plasma prepared using HelinxTM technology is efficacious and well tolerated in treatment of end\u2010stage liver disease patients\u2014the STEP AC trial",
            "authors": [],
            "year": 2001,
            "venue": "Blood",
            "volume": "98",
            "issn": "Suppl 1",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF33": {
            "title": "Why \u201csafer than ever\u201d may not be safe enough",
            "authors": [],
            "year": 2004,
            "venue": "Transfus Med Hemother",
            "volume": "31",
            "issn": "Suppl 1",
            "pages": "2-10",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF34": {
            "title": "Preparation of cryoprecipitate from photochemically treated fresh frozen plasma",
            "authors": [],
            "year": 2000,
            "venue": "Transfusion",
            "volume": "40",
            "issn": "Suppl 1",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF35": {
            "title": "Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S\u201059) and ultraviolet A light",
            "authors": [],
            "year": 2005,
            "venue": "Transfusion",
            "volume": "45",
            "issn": "",
            "pages": "1453-8",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF36": {
            "title": "Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers",
            "authors": [],
            "year": 1990,
            "venue": "J Clin Microbiol",
            "volume": "28",
            "issn": "",
            "pages": "2030-4",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF37": {
            "title": "Identification of HTLV\u2010I\u2010 or HTLV\u2010II\u2010producing cells by cocultivation with BHK\u201021 cells stably transfected with a LTR\u2010lacZ gene construct",
            "authors": [],
            "year": 1995,
            "venue": "J Virol Meth",
            "volume": "51",
            "issn": "",
            "pages": "19-29",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF38": {
            "title": "Photochemical decontamination of blood components containing hepatitis B and non\u2010A, non\u2010B virus",
            "authors": [],
            "year": 1988,
            "venue": "Lancet",
            "volume": "2",
            "issn": "",
            "pages": "1446-50",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF39": {
            "title": "Non\u2010A, non\u2010B hepatitis in chimpanzees and marmosets",
            "authors": [],
            "year": 1981,
            "venue": "J Infect Dis",
            "volume": "144",
            "issn": "",
            "pages": "588-98",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF40": {
            "title": "Experimental transmission of duck hepatitis B virus to Pekin ducks and to domestic geese",
            "authors": [],
            "year": 1987,
            "venue": "Hepatology",
            "volume": "7",
            "issn": "",
            "pages": "724-31",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF41": {
            "title": "Infectious cDNA clone of the epidemic west nile virus from New York City",
            "authors": [],
            "year": 2002,
            "venue": "J Virol",
            "volume": "76",
            "issn": "",
            "pages": "5847-56",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF42": {
            "title": "Photosensitized inactivation of Plasmodium falciparum\u2010 and Babesia divergens\u2010infected erythrocytes in whole blood by lipophilic pheophorbide derivatives",
            "authors": [],
            "year": 1997,
            "venue": "Vox Sang",
            "volume": "72",
            "issn": "",
            "pages": "211-20",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF43": {
            "title": "Methods for detecting Babesia microti infection in wild rodents",
            "authors": [],
            "year": 1980,
            "venue": "J Parasitol",
            "volume": "66",
            "issn": "",
            "pages": "107-10",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF44": {
            "title": "Window\u2010period human immunodeficiency virus transmission to two recipients by an adolescent blood donor",
            "authors": [],
            "year": 2004,
            "venue": "Transfusion",
            "volume": "44",
            "issn": "",
            "pages": "929-33",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF45": {
            "title": "Intermittent low\u2010level viremia in very early primary HIV\u20101 infection",
            "authors": [],
            "year": 2005,
            "venue": "J Acquir Immune Defic Syndr",
            "volume": "39",
            "issn": "",
            "pages": "133-7",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF46": {
            "title": "Virus inactivated single\u2010donor fresh plasma preparations",
            "authors": [],
            "year": 1992,
            "venue": "Infusionsther Transfusionsmed",
            "volume": "19",
            "issn": "",
            "pages": "79-83",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF47": {
            "title": "Methylene blue\u2010treated fresh\u2010frozen plasma: what is its contribution to blood safety?",
            "authors": [],
            "year": 2003,
            "venue": "Transfusion",
            "volume": "43",
            "issn": "",
            "pages": "1322-9",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF48": {
            "title": "Solvent/detergent\u2010treated plasma: a virus\u2010inactivated substitute for fresh frozen plasma",
            "authors": [],
            "year": 1992,
            "venue": "Blood",
            "volume": "79",
            "issn": "",
            "pages": "826-31",
            "other_ids": {
                "DOI": []
            }
        }
    }
}